Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,951 public trials 2,018 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, Not Recruiting

A Study of MCARH109 and MCARH125 in People With Multiple Myeloma

NCT05431608

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Memorial Sloan Kettering Basking Ridge (Limited protocol activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited protocol activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited protocol activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Commack (Limited protocol activities) Commack, New York, United States
View Trial Details
Active, Not Recruiting

A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma

NCT04416451

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • City of Hope Cancer Center (Data collection only) Duarte, California, United States
  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (All protocol activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (All protocol Activities) Montvale, New Jersey, United States
View Trial Details
Active, Not Recruiting

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

NCT04181827

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Mayo Clinic Cancer Center-Scottsdale Phoenix, Arizona, United States
  • Stanford University Medical Center Stanford, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
View all 88 locations
View Trial Details
Active, Not Recruiting

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

NCT06604715

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Princess Margaret Hospital Toronto, Ontario, Canada
  • Jewish General Hospital Montreal, Quebec, Canada
  • Seoul National University Hospital Seoul, South Korea
  • Asan Medical Center Seoul, South Korea
View all 15 locations
View Trial Details
Active, Not Recruiting

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

NCT05050097

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Alabama Birmingham Birmingham, Alabama, United States
  • University of California San Francisco San Francisco, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Emory University Atlanta, Georgia, United States
View all 31 locations
View Trial Details
Active, Not Recruiting

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT03533283

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • UZ Gent Ghent, Belgium
  • Aarhus Universitetshospital Skejby Aarhus N, Denmark
  • Rigshospitalet København Ø, Denmark
  • Odense Universitetshospital Odense C, Denmark
View all 19 locations
View Trial Details
Active, Not Recruiting

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

NCT04923893

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • UCSF San Francisco, California, United States
  • Yale Cancer Center New Haven, Connecticut, United States
  • University of Miami Health System Miami, Florida, United States
  • AdventHealth Cancer Institute Orlando, Florida, United States
View all 136 locations
View Trial Details
Active, Not Recruiting

A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma

NCT06550895

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Iowa Hospital and Clinics Iowa City, Iowa, United States
  • Norton Cancer Institute Louisville, Kentucky, United States
  • Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States
  • Icahn School of Medicine at Mount Sinai New York, United States
View Trial Details
Active, Not Recruiting

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

NCT06356129

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations
  • Local Institution - 0014 Mobile, Alabama, United States
  • Local Institution - 0477 Anchorage, Alaska, United States
  • Local Institution - 0452 Phoenix, Arizona, United States
  • Local Institution - 0342 San Francisco, California, United States
View all 325 locations
View Trial Details

Related conditions